Author:
Fleischmann Edith,Marschalek Corinna,Schlemitz Katja,Dalton Jarrod E,Gruenberger Thomas,Herbst Friedrich,Kurz Andrea,Sessler Daniel I
Abstract
Abstract
Background
Even the best cancer surgery is usually associated with minimal residual disease. Whether these remaining malignant cells develop into clinical recurrence is at least partially determined by adequacy of host defense, especially natural killer cell function. Anesthetics impair immune defenses to varying degrees, but nitrous oxide appears to be especially problematic. We therefore tested the hypothesis that colorectal-cancer recurrence risk is augmented by nitrous oxide administration during colorectal surgery.
Methods
We conducted a 4- to 8-year follow-up of 204 patients with colorectal cancer who were randomly assigned to 65% nitrous oxide (n = 97) or nitrogen (n = 107), balanced with isoflurane and remifentanil. The primary outcome was the time to cancer recurrence. Our primary analysis was a multivariable Cox-proportional-hazards regression model that included relevant baseline variables. In addition to treatment group, the model considered patient age, tumor grade, dissemination, adjacent organ invasion, vessel invasion, and the number of nodes involved. The study had 80% power to detect a 56% or greater reduction in recurrence rates (i.e., hazard ratio of 0.44 or less) at the 0.05 significance level.
Results
After adjusting for significant baseline covariables, risk of recurrence did not differ significantly for nitrous oxide and nitrogen, with a hazard ratio estimate (95% CI) of 1.10 (0.66, 1.83), P = 0.72. No two-way interactions with the treatment were statistically significant.
Conclusion
Colorectal-cancer recurrence risks were not greatly different in patients who were randomly assigned to 65% nitrous oxide or nitrogen during surgery. Our results may not support avoiding nitrous oxide use to prevent recurrence of colorectal cancer.
Implications Statement
The risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.
Trial Registration
Current Controlled Clinical Trials NCT00781352 http://www.clinicaltrials.gov
Publisher
Springer Science and Business Media LLC
Subject
Anesthesiology and Pain Medicine
Reference29 articles.
1. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K: Tumor cells in blood shed from the surgical field. Arch Surg. 1995, 130 (4): 387-393.
2. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001, 2 (4): 293-299. 10.1038/86297.
3. Matsushima T: Experimental studies of blood-borne metastasis and induced tumor in injured lung. Kumamoto Med J. 1969, 22 (2): 83-98.
4. Ben-Eliyahu S: The price of anticancer intervention. Does surgery promote metastasis?. Lancet Oncol. 2002, 3 (9): 578-579.
5. Shapiro J, Jersky J, Katzav S, Feldman M, Segal S: Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. J Clin Invest. 1981, 68 (3): 678-685. 10.1172/JCI110303.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Anesthesia and cancer recurrence: a narrative review;Anesthesia and Pain Medicine;2024-04-30
2. Anesthesia and cancer;Revista da Associação Médica Brasileira;2024
3. Ca Rectum for Laparoscopic Abdomino-Perineal Resection;Problem Based Learning Discussions in Onco-Anesthesia and Onco-Critical Care;2024
4. Anesthesia and Cancer Recurrence;Textbook of Onco-Anesthesiology;2021
5. Anesthesia Practices in Colorectal Cancer Surgery;Colon Polyps and Colorectal Cancer;2020-10-30